+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Amgen

  • ID: 5357341
  • Company Profile
  • January 2021
  • 48 pages
  • Datamonitor Healthcare
  • Amgen Inc.
The publisher explores Amgen’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - PharmaVitae forecasts Amgen’s sales to grow out to 2029.
  • Key themes - [1] Successful resolution of Enbrel litigation a major positive for Amgen, as patent protection secured into 2029 [2] Pipeline has a few potential blockbusters, with tezepelumab and AMG 510 [3] Acquisition of Otezla adds a substantial boost to revenue in both near and long term, adding over $3bn by 2023 [4] Acquisition of Amgen Astellas BioPharma and 20.5% equity stake in BeiGene significantly transforms Amgen’s long-term strategy for the Asian market.
Model updates (3 November 2020)
  • Kanjinti forecast adjusted higher
  • Mvasi forecast adjusted higher.
Model updates (30 July 2020)
  • Prolia forecast adjusted lower due to impact from COVID-19
  • Aimovig forecast adjusted lower due to sales trends
  • Kanjinti forecast adjusted higher due to continued share gains
  • Mvasi forecast adjusted higher due to continued share gains
  • Neulasta forecast adjusted higher due to stronger trends from Onpro
  • Avsola forecast added after recent product launch.
Model updates (20 May 2020)
  • Prolia forecast adjusted lower due to impact from COVID-19
  • AMG 510 forecast adjusted lower due to updated trial results presented at ASCO.
Model updates (4 March 2020)
  • Mvasi forecast added due to Amgen providing brand-level revenue detail on biosimilars business
  • Kanjinti forecast added due to Amgen providing brand-level revenue detail on biosimilars business
  • Amgevita forecast added due to Amgen providing brand-level revenue detail on biosimilars business
  • ABP 798 forecast added.
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll